Dendreon Rises on Takeover Chatter (DNDN, LLY, AMGN)
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Dendreon Corp. (NASDAQ: DNDN), maker of prostate cancer drug Provenge, is once again rumored to be a takeover target. As Streetinsider.com points out, the company’s new chairman presided over the Eli Lilly & Co. (NYSE: LLY) takeover of ImClone, which only stokes the rumor mill.
Amgen Inc. (NASDAQ: AMGN), whose bone pain drug, Xgeva, failed to get an FDA panel’s approval for use as a treatment for prostate cancer, is most often mentioned as a potential suitor for Dendreon. Dendreon’s market cap of around $1.5 billion is well within Amgen’s scope.
Dendreon’s shares are up more than 4.5% at $10.39 in a 52-week range of $6.46-$43.96.
Contact [email protected] for any questions or corrections.